Inventor
DING XIAO
CN21 patents
⚠️ This page may combine multiple inventors who share the name “DING XIAO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
INSILICO MEDICINE IP LTD
8 patentsUS11780854B2Oct 10, 2023
Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof
INSILICO MEDICINE IP LTD1 citations70
US11731987B2Aug 22, 2023
Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof
INSILICO MEDICINE IP LTD3 citations70
US12209101B2Jan 28, 2025
Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof
INSILICO MEDICINE IP LTD0 citations59
US12071443B2Aug 27, 2024
Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof
INSILICO MEDICINE IP LTD0 citations59
US11731944B2Aug 22, 2023
SARS-CoV-2 inhibitors for treating coronavirus infections
INSILICO MEDICINE IP LTD1 citations53
US12103915B2Oct 1, 2024
TEAD inhibitors and methods of uses thereof
INSILICO MEDICINE IP LTD0 citations47
US11999713B2Jun 4, 2024
Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof
INSILICO MEDICINE IP LTD0 citations47
US12077538B2Sep 3, 2024
Diacylglycerol kinase (DGK) alpha inhibitors and uses thereof
INSILICO MEDICINE IP LTD0 citations46
GLAXOSMITHKLINE IP DEV LTD
5 patentsUS9815841B2Nov 14, 2017
Compounds
GLAXOSMITHKLINE IP DEV LTD2 citations69
US10975081B2Apr 13, 2021
Substituted fused pyrazole compounds and their use as LRRK2 inhibitors
GLAXOSMITHKLINE IP DEV LTD1 citations61
US10618901B2Apr 14, 2020
LRRK2 inhibitors for the treatment of Parkinson's disease
GLAXOSMITHKLINE IP DEV LTD1 citations60
US10087186B2Oct 2, 2018
Compounds as LRRK2 kinase inhibitors
GLAXOSMITHKLINE IP DEV LTD1 citations50
US10858367B2Dec 8, 2020
Compounds
GLAXOSMITHKLINE IP DEV LTD0 citations39
SIGMA ALDRICH CO LLC
3 patentsUS10604752B2Mar 31, 2020
Using nucleosome interacting protein domains to enhance targeted genome modification
SIGMA ALDRICH CO LLC6 citations81
US12065642B2Aug 20, 2024
Using nucleosome interacting protein domains to enhance targeted genome modification
SIGMA ALDRICH CO LLC1 citations71
US12221606B2Feb 11, 2025
Using nucleosome interacting protein domains to enhance targeted genome modification
SIGMA ALDRICH CO LLC0 citations60